Dr. Jessica DesNoyer, PhD, MBA – Chief Executive Officer, Ostiio
Jessica is CEO of Ostiio, a seed-stage medical device startup focused on improving the lives of people with craniofacial abnormalities. An accomplished healthcare and life sciences executive, Jessica brings a track record of building innovation centers and emerging businesses within several large corporates (J&J DePuy Synthes, Smith & Nephew, Abbott, and Becton Dickinson) to the Ostiio team.
Prior to joining Ostiio, Jessica enjoyed a successful and rewarding career that encompassed a diverse background across therapy spaces (interventional, cardiovascular, and orthopedics), technologies (devices, biologics/biomaterials, and combination therapies), and functional leadership roles (R&D, strategy & innovation, marketing, business development, and general management). Her education, experience, and passion uniquely position her to guide technology from concept through commercialization. Throughout her career, she has enthusiastically led cross-functional teams to build and execute global operational plans that supported a diverse portfolio of product clearances/approvals and their subsequent commercialization.
Most recently, Jessica was Sr Director, Global Strategic Marketing of DePuy Synthes, a Johnson & Johnson Company, where she helped drive turnaround of the declining Spine business through leadership of Platform strategy, business development initiatives, and commercial execution of the global $250M Biomaterials portfolio. Before that, she was VP, Marketing & Business Development of MicroMedicine, where she helped secure $35M in financing and developed a business plan for the novel microfluidic cell isolation technology startup. Jessica also served as Head of Strategic Innovation for Becton Dickinson’s largest Division, Medication & Procedural Solutions, and established and led Smith & Nephew’s Advanced Healing Technologies franchise, an internal startup aimed at improving outcomes in sports medicine and orthopedic surgery through biologics and biomaterials solutions.
Jessica began her career at Guidant/Abbott Vascular where she helped develop and launch the world’s leading Drug Eluting Stent, the XIENCE/PROMUS system; spearheaded the company’s Vulnerable Plaque program for heart attack prevention; and built the Structural Heart market access strategy, culminating in the $320M acquisition of Evalve, Inc.
Jessica holds an MBA from the Wharton School of Business at the University of Pennsylvania, a PhD in Chemical Engineering from the University of Illinois at Urbana-Champaign, and a BSE in Chemical Engineering from the University of Michigan.